Hyperuricemia is a major risk factor for many chronic diesease. Recently, gut mcirobiota has been identified as a novel theraputic target for hyperuricemia. Both annimal studies and pilot human trials have demonstrated that administration of prebiotics help delay the progression of hyperuricemia throuh several mechanisms. This trial aims to examine its protective effects and potential mechanisms in clinical trials.
Hyperuricemia is a major risk factor for many chronic diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of hyperuricemia. Animal studies have demonstrated that administration of prebiotics help delay the progression of hyperuricemia through several mechanisms such as reduction in endotoxemia, and enhanced production of short-chain fatty acids and hippuric acid. However, whether administration of prebiotics also has a protective effect in subjects with hyperuricemia remain under-explored. Moreover, whether the original gut microbiota will influence the protective effect of prebiotics remains largely unknown.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
160
During the study period, subjects are instructed to take one pocket of arabosylan per day during the first week, followed by two pockets of araboxylan per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
During the study period, subjects are instructed to take one pocket of inulin per day during the first week, followed by two pockets of inulin per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
Department of Nutrition and Food Hygiene
Guangzhou, Guangdong, China
RECRUITINGSun Yat-Sen University
Guangzhou, Guangdong, China
RECRUITINGChange of serum uric acid
change of fasting uric acid level assessed by biochemical detector
Time frame: from baseline to 12 weeks after intervention
Change of excretion of uric acid
excretion rate of uric acid assessed by secretion rate of uric acid in urine during 3 hours
Time frame: from baseline to 12 weeks after intervention
Change of gut microbiota
Alterations of the composition of gut microbiota evaluated by metagenomics
Time frame: from baseline to 12 weeks after intervention
Change of microbial metabolites
Untargeted metabolomics will be used to assess the alterations of microbial metabolites with high performance liquid chromatography-mass spectrometry
Time frame: from baseline to 12 weeks after intervention
Change in insulin sensitivity
HOMA-IR will be used to assess the change of insulin sensitivity
Time frame: from baseline to 12 weeks after intervention
Change in waist circumference
change in waist circumference assessed by tape
Time frame: from baseline to 12 weeks after intervention
Change in blood pressure
change in blood pressure assessed by electronic sphymomanometer
Time frame: from baseline to 12 weeks after intervention
Change in lipid profiles
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
During the study period, subjects are instructed to take one pocket of inulin and araboxylan per day during the first week, followed by two pockets of inulin and araboxylan per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
During the study period, subjects are instructed to take one pocket of placebo control per day during the first week, followed by two pockets of placebo control per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
change in total cholesterol, triglycerides, LDL-c and HDL-c assessed by biochemical detector
Time frame: from baseline to 12 weeks after intervention